Reports
Sale
Global Diabetes Drugs Market Size, Share, Trends, Analysis, Forecast: By Drugs: Oral Anti-diabetic Drugs, Insulin; By Diabetes Type: Type I, Type II; By Distribution Channel: Online Retailers, Hospital Pharmacies, Retail Pharmacies; By End User: Hospital, Clinics, Personal Use, Other; Regional Analysis; Supplier Landscape; 2024-2032
Global Diabetes Drugs Market Outlook
The global diabetes drugs market value was USD 74.48 billion in 2023, driven by the increasing prevalence of diabetes across the globe. The market is forecasted to grow at a CAGR of 5.3% during the forecast period of 2024-2032 to achieve a value of USD 118.55 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Asia Pacific to be Among the Leading Regions Owing to the Increasing Diabetic Population
The Asia Pacific region accounts for a significant share of the global market as it has a large diabetic population, China alone has more than 120 million diabetic people, and the number does not seem to stop. The rising number of diabetes patients can be due to multiple reasons, such as changing lifestyles, unhealthy diet, overconsumption of junk food, and obesity, among others. Looking at the scenario, various companies are developing new and cost-effective alternatives, anti-diabetic drugs. They have started advertising their products and treatments to spread awareness about the same. In addition to favourable government reimbursement policies, increasing development for insulins and improving healthcare infrastructure are propelling the market for diabetic drugs.
The growing inclination toward junk foods is a major factor why people become diabetic. The lifestyle is becoming increasingly hectic, and the inclination toward junk and processed foods is constantly rising, which keeps the need for constant development in the medical field alive. New drugs, such as Canagliflozin and dapagliflozin, are getting approved for the treatment of diabetes, which opens up numerous opportunities for both new and established competitors in the global diabetic medications industry.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Segmentations: Diabetes Drugs Market
Diabetes is a disease that occurs when the blood sugar levels rise up to extremely high levels, affecting body functions and other disruptions in the body. It is a chronic disease, and the types can be divided into Type1 and Type2. Diabetes drugs are used to control the sugar level through oral administration of insulin in the main treatment.
The drug types in the market can be divided into the following:
- Oral Anti-Diabetic Drugs
- Alpha-Glucosidase Inhibitors
- Biguanides
- Bile Acid Sequestrants
- Dopamine-2 Agonists
- DPP-4 inhibitors
- Meglitinides
- SGLT2 Inhibitors
- Sulfonylureas
- TZDs
- Oral Combination Therapy
- Insulin
- Insulin Glargine
- Insulin Aspart
- Human Insulin
- Biosimilar Insulin
The types of diabetes can be divided into the following:
- Type 1
- Type 2
The distribution channels of the diabetes drug market
- Online
- Hospital
- Retail Pharmacies
The regional markets for diabetes drugs market can be divided into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The Increasing Diabetic Population Propelling the Market Growth
The market growth is majorly driven by the increasing cases of diabetes every day around the world. The degrading lifestyle and eating habits like excessive sugar-based food consumption, which does not seem to improve, are major reasons of concern as they can transform into other disorders like obesity, liver problems, and diabetes, among others. The demand for insulin is rising due to the increasing cases and especially among the type 1 diabetics, as the intake is greater in them.
To combat this ongoing issue, governments are increasing their investment in R&D. Healthcare organisations and pharmaceutical manufacturers are increasingly collaborating with the government to develop new products and cost-effective methods to support a wider group of population. The number of diabetes care centres is aiding the growth of the diabetes drugs market. Technological advancements in the diabetes diagnostics devices, such as portable glucometers, make it possible for people to track their blood glucose levels, and the increasing availability of these devices will drive the growth of the market as when the people become aware of the situation, they will be more likely to get treatment, which simultaneously raises the market for diabetes drugs.
Key Players in the Global Market for Diabetic Drugs
The report gives a detailed analysis of the following key players in the global diabetes drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Novo Nordisk A/S
- Sanofi-aventis Groupe
- Merck & Co., Inc.
- Eli Lilly and Company.
- AstraZeneca plc
- Takeda Pharmaceutical Company Limited.
- Novartis AG
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drugs |
|
| Breakup by Diabetes Type |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Diabetes Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Diabetes Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Diabetes Epidemiology (2016-2031)
5.3 Europe Diabetes Epidemiology (2016-2031)
5.4 Asia-Pacific Diabetes Epidemiology (2016-2031)
5.5 Latin America Diabetes Epidemiology (2016-2031)
5.6 Middle East & Africa Diabetes Epidemiology (2016-2031)
6 Global Diabetes Drugs Market Overview
6.1 Global Diabetes Drugs Market Historical Value (2017-2023)
6.2 Global Diabetes Drugs Market Forecast Value (2024-2032)
7 Global Diabetes Drugs Market Landscape
7.1 Diabetes Drugs: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Diabetes Drugs: Product Landscape
7.2.1 Analysis by Drug
7.2.2 Analysis by Diabetes Type
7.2.3 Analysis by Distribution Channel
7.2.4 Analysis by End User
8 Diabetes Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Diabetes Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Diabetes Drugs Market Segmentation
11.1 Global Diabetes Drugs Market by Drugs
11.1.1 Market Overview
11.1.2 Oral Anti-diabetic Drugs
11.1.2.1 Alpha-glucosidase Inhibitor
11.1.2.2 Biguanides
11.1.2.3 Bile Acid Sequestrants
11.1.2.4 Dopamine-2 Agonists
11.1.2.5 DPP-4 Inhibitors
11.1.2.6 Meglitinides
11.1.2.7 SLGT2 Inhibitors
11.1.2.8 Sulfonylureas
11.1.2.9 TZDs
11.1.2.10 Oral Combination Therapy
11.1.3 Insulin
11.1.3.1 Insulin Glargine
11.1.3.2 Insulin Aspart
11.1.3.3 Human Insulin
11.1.3.4 Biosimilar Insulin
11.2 Global Diabetes Drugs Market by Diabetes Type
11.2.1 Market Overview
11.2.2 Type I
11.2.3 Type II
11.3 Global Diabetes Drugs Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Online Retailers
11.3.3 Hospital Pharmacies
11.3.4 Retail Pharmacies
11.4 Global Diabetes Drugs Market by End User
11.4.1 Market Overview
11.4.2 Hospital
11.4.3 Clinics
11.4.4 Personal Use
11.4.5 Other
11.5 Global Diabetes Drugs Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Diabetes Drugs Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Diabetes Drugs Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Diabetes Drugs Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Diabetes Drugs Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Diabetes Drugs Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Eli Lilly and Company
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 AstraZeneca Plc.
23.2.1 Novo Nordisk A/S
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Sanofi-aventis Groupe
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Merck & Co., Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Home Diagnostics Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Takeda Pharmaceutical Company Limited.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Boehringer Ingelheim International GmbH
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Novo Nordisk A/S
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Ypsomed AG
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Ascensia Diabetes Care Holdings AG
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Dexcom, Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Sanofi-Deutschland GmbH
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Roche Products Limited
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
24 Diabetes Drugs - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
Globally, Diabetes Drugs market reached a value of USD 74.48 billion in 2023.
The market is projected to expand at a CAGR of 5.3% from 2024 to 2032, growing to USD 118.55 billion by 2032.
The major drivers include the rapidly increasing diabetic population, rising investments in the R&D for better treatment, technological advancements, and the rising consumption of food with sugar, lack of exercise, and unhealthy diets.
The rising investment by the government in drug development is a key industry trend driving the market growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with Asia Pacific accounting for the largest share of the market.
The types of drugs can be divided into oral anti-diabetic drugs and insulin. Oral anti-diabetic drugs can be further divided into Alpha-glucosidase inhibitors, Biguanides, Bile Acid Sequestrants, Dopamine-2 Agonists, DPP-4 inhibitors, Meglitinides, SGLT2 Inhibitors, Sulfonylureas, TZDs, and oral combination therapy. Insulin can be further divided into Insulin Glargine, Insulin Aspart, Human Insulin, and Biosimilar Insulin.
The types of diabetes can be divided into Type 1 and Type 2.
The different distribution channels include online, hospital, and retail pharmacies.
The major players in the industry are Novo Nordisk A/S, Sanofi-aventis Groupe, Merck & Co. Inc., Eli Lilly and Company., AstraZeneca plc, Takeda Pharmaceutical Company Limited., and Novartis AG, among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER